[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-406707-105":59,"doc-detail-406707-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","comparison-of-parathormone-lowering-effects-of-paricalcitol-and-calcitriol-in-hemodialysis-patients-prospective-study","Comparison of parathormone lowering effects of paricalcitol and calcitriol in hemodialysis patients - Prospective Study","","Parathyroid hormone (PTH) levels can fluctuate in hemodialysis patients due to changes in calcium, phosphorus, and vitamin D. Clinical guidelines recommend maintaining PTH within two to nine times the upper normal limit to help prevent renal osteodystrophy, and vitamin D receptor agonists are used when hyperparathyroidism exceeds recommended ranges. This prospective study compared real-world PTH-lowering effects of paricalcitol versus calcitriol and evaluated reductions over six months, safety outcomes, and the ability to maintain target PTH ranges.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/comparison-of-parathormone-lowering-effects-of-paricalcitol-and-calcitriol-in-hemodialysis-patients-prospective-study/406707/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/comparison-of-parathormone-lowering-effects-of-paricalcitol-and-calcitriol-in-hemodialysis-patients-prospective-study/406707.png","ImageObject",300,407,{"name":92,"@type":93},"Kurz","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are parathyroid hormone (PTH) levels important in hemodialysis patients?","Question",{"text":112,"@type":113},"The document states that controlling PTH is crucial to decrease fracture risk and improve survival. PTH levels also must be maintained within recommended ranges to prevent renal osteodystrophy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the study compare paricalcitol and calcitriol treatment?",{"text":117,"@type":113},"Patients with PTH levels exceeding nine times the upper normal limit were assigned based on patient preference to intravenous calcitriol (2 μg at the end of each dialysis session) or intravenous paricalcitol (5 μg twice per week). Outcomes included changes in PTH over six months and achievement of 25% and 50% reductions.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main results regarding PTH reduction and safety?",{"text":121,"@type":113},"Paricalcitol achieved a 50% PTH reduction more often than calcitriol (62.5% vs 7.6%), with statistical significance. There was no significant difference for achieving a 25% reduction, and both treatments did not show clinically important hyperphosphatemia or hypercalcemia.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},406707,1790879825,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},2336478945635,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","| W | J | N | World Journal of\u003Cbr>Nephrology |\n| --- | --- | --- | --- |\n\nSubmit a Manuscript: [https://www.f6publishing.com](https://www.f6publishing.com) World J Nephrol 2025 December 25; 14(4): 110817  \nDOI: 10.5527/wjn.v14.i4.110817 ISSN 2220-6124 (online)  \nORIGINAL ARTICLE  \nProspective Study  \nComparison of parathormone lowering effects of paricalcitol and calcitriol in hemodialysis patients  \nAhmet Murt  \nSpecialty type: Urology and nephrology  \nProvenance and peer review:  \nInvited article; Externally peer reviewed.  \nPeer-review model: Single blind  \nPeer-review report’s classification Scientific Quality: Grade C  \nNovelty: Grade B, Grade D  \nCreativity or Innovation: Grade B, Grade D  \nScientific Significance: Grade B, Grade C  \nP-Reviewer: Feng F, MD, China; Mzhavanadze ND, PhD, Associate Professor, Russia  \nReceived: June 16, 2025  \nRevised: July 20, 2025  \nAccepted: October 28, 2025  \nPublished online: December 25, 2025  \nProcessing time: 190 Days and 14.6 Hours  \nAhmet Murt, Department of Nephrology Clinic, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Istanbul 34000, Türkiye  \nCorresponding author: Ahmet Murt, Department of Nephrology Clinic, Istanbul UniversityCerrahpasa, Cerrahpasa Medical Faculty, No. 53 Kocamustafapaşa Caddesi, Istanbul 34000, Tü[rkiye.](rkiye. ahmet.murt@istanbul.edu.tr)[ ahmet.murt@istanbul.edu.tr](rkiye. ahmet.murt@istanbul.edu.tr)  \nAbstract  \nBACKGROUND  \nParathyroid hormone (PTH) levels may fluctuate in patients undergoing hemodialysis because of changes in calcium, phosphorus, and vitamin D levels. For these patients, the “Kidney Disease: Improving Global Outcomes” clinical practice guidelines recommend PTH levels be maintained in the range of two to nine times of the upper normal limit. Maintaining this balance is critical to prevent renal osteodystrophy. When the severity of hyperparathyroidism exceeds the recommended limits, vitamin D receptor agonists may be used for lowering PTH levels. Paricalcitol, as a biologically active vitamin D analog, is a selective activator of vitamin D responsive pathways. Both calcitriol and paricalcitol can be used as PTHlowering agents. There is conflicting data about their comparative effectiveness for controlling hyperparathyroidism in patients undergoing hemodialysis and a meta-analysis revealed no differences between the two.  \nAIM  \nTo give real world data comparing paricalcitol and calcitriol as PTH-lowering agents in patients undergoing hemodialysis.  \nMETHODS  \nPatients undergoing hemodialysis whose PTH levels exceeded nine times of the upper normal limit were enrolled in the study. Depending on patient preferences, they were either given calcitriol or paricalcitol. Intravenous calcitriol was given 2 μg at the end of each dialysis sessions, and intravenous paricalcitol was administered as 5 μg twice per week. Demographic data, calcium-phosphorus levels, change in PTH levels in 6 months, and ratios of 25% and 50% reductions in PTH levels were compared between the two groups.  \nRESULTS  \nA total of 21 patients were enrolled in this comparative study, eight patients received paricalcitol and 13 were prescribed calcitriol. A 50% reduction in PTH  \n WJN  [https://www.wjgnet.com](https://www.wjgnet.com) 1 December 25, 2025  Volume 14  Issue 4   \nMurt A. Paricalcitol vs calcitriol in hemodialysis patients  \nlevels could be achieved in five patients in the paricalcitol group (62.5%); only one patient in the calcitriol group achieved the same reduction (7.6%). The difference was statistically significant (P = 0.014) . However, there was no difference in the ratio of patients who had a 25% reduction in PTH levels (87.5% vs 38.4%; P = 0.067) . PTH levels could be maintained in the targeted range in 87.5% of the patients in the paricalcitol group and in 69.2% of the patients in the calcitriol group (P = 0.36). However, PTH could be better suppressed under paricalcitol. Clinically important hyperphosphatemia or hypercalcemia was not observ","cbCail6QqY71Ujyh","https://ap.wps.com/l/cbCail6QqY71Ujyh","pdf",409086,"English","# Abstract\n## Background\n## Aim\n## Methods\n## Results\n## Conclusion\n# Core Tip","[{\"question\":\"Why are parathyroid hormone (PTH) levels important in hemodialysis patients?\",\"answer\":\"The document states that controlling PTH is crucial to decrease fracture risk and improve survival. PTH levels also must be maintained within recommended ranges to prevent renal osteodystrophy.\"},{\"question\":\"How did the study compare paricalcitol and calcitriol treatment?\",\"answer\":\"Patients with PTH levels exceeding nine times the upper normal limit were assigned based on patient preference to intravenous calcitriol (2 μg at the end of each dialysis session) or intravenous paricalcitol (5 μg twice per week). Outcomes included changes in PTH over six months and achievement of 25% and 50% reductions.\"},{\"question\":\"What were the main results regarding PTH reduction and safety?\",\"answer\":\"Paricalcitol achieved a 50% PTH reduction more often than calcitriol (62.5% vs 7.6%), with statistical significance. There was no significant difference for achieving a 25% reduction, and both treatments did not show clinically important hyperphosphatemia or hypercalcemia.\"}]","Comparison of parathormone lowering effects of paricalcitol and calcitriol in hemodialysis patients - Prospective Study | PDF",1790567446,18]